Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taha Merghoub

Showing results (181-190 of 216) with videos related to

Pageof 22
Sort By:
Cell|April 17, 2018
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 BlockadeSachet A Shukla, Pavan Bachireddy, Bastian Schilling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2018
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation SequencingHira Rizvi, Francisco Sanchez-Vega, Konnor La, et al.
Nature|October 8, 2015
Alternative transcription initiation leads to expression of a novel ALK isoform in cancerThomas Wiesner, William Lee, Anna C Obenauf, et al.
Nature|May 31, 2022
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric CancerSteven B Maron, Walid Chatila, Henry Walch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 23, 2019
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung CancerJiajia Zhang, Zhicheng Ji, Justina X Caushi, et al.
Molecular Cell|July 7, 2015
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 SignalingHee-Bum Kang, Jun Fan, Ruiting Lin, et al.
Cell|June 25, 2021
Pharmacologic modulation of RNA splicing enhances anti-tumor immunitySydney X Lu, Emma De Neef, James D Thomas, et al.
Nature|May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Cell|March 31, 2023
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variantsDaniel Hirschhorn, Sadna Budhu, Lukas Kraehenbuehl, et al.
Pageof 22

Showing results (181-190 of 216) with videos related to

Sort By:
Pageof 22
Cell|April 17, 2018
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 BlockadeSachet A Shukla, Pavan Bachireddy, Bastian Schilling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2018
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation SequencingHira Rizvi, Francisco Sanchez-Vega, Konnor La, et al.
Nature|October 8, 2015
Alternative transcription initiation leads to expression of a novel ALK isoform in cancerThomas Wiesner, William Lee, Anna C Obenauf, et al.
Nature|May 31, 2022
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric CancerSteven B Maron, Walid Chatila, Henry Walch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 23, 2019
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung CancerJiajia Zhang, Zhicheng Ji, Justina X Caushi, et al.
Molecular Cell|July 7, 2015
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 SignalingHee-Bum Kang, Jun Fan, Ruiting Lin, et al.
Cell|June 25, 2021
Pharmacologic modulation of RNA splicing enhances anti-tumor immunitySydney X Lu, Emma De Neef, James D Thomas, et al.
Nature|May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Cell|March 31, 2023
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variantsDaniel Hirschhorn, Sadna Budhu, Lukas Kraehenbuehl, et al.
Pageof 22